Investor Relations

Corporate Profile

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.

Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).

We are currently evaluating vibegron in a pivotal Phase 3 international clinical trial for the treatment of OAB. We also plan to commence a Phase 3 clinical trial for OAB in men with BPH and a Phase 2a clinical trial for IBS-associated pain by the end of 2018. We intend to continue to expand our pipeline with the goal of creating a leading urology company by developing, commercializing and acquiring innovative therapies.

Urovant’s second investigational product candidate, hMaxi-K, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
September 26, 2018
Urovant Sciences Ltd. Announces Pricing of Initial Public Offering
BASEL, Switzerland and IRVINE, Calif. , Sept. 26, 2018 /PRNewswire/ -- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today announced the pricing of its initial public offering of 10,000,000 common shares at
Additional Formats
August 28, 2018
Urovant Sciences Licenses Novel Gene Therapy for Overactive Bladder
There are no currently available FDA-approved gene therapy treatments for overactive bladder Urovant expects to initiate Phase 2 hMaxi-K study in 2019 BASEL, Switzerland and IRVINE, Calif., August 28, 2018/PRNewswire – Urovant Sciences, a clinical-stage biopharmaceutical company focused on
Additional Formats
Events
More events are coming soon.